Prof. Mark Emberton, Professor of Urology
Prof. Mark Emberton
Professor of Urology
Prof. Mark Emberton MD FRCS Urol
Professor of Urology
Areas of expertise
- Focal therapy
- Minimally invasive treatment for prostate cancer which aims to preserve prostate and aims to preserve function
- Non-invasive diagnosis incorporating MRI and targeted biopsies where necessary
- Use of biomarkers to refine the risk stratification of men who've been recently diagnosed with prostate cancer
Recommendations for Prof. Emberton
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
About Prof. Mark Emberton
GMC number: 3098619
Year qualified: 1985
Place of primary qualification: University of London
Initial consultation fee: £340
Follow up consultation fee: £230
Prof. Mark Emberton is a Consultant Urological Surgeon and Professor of Interventional Oncology, specialising in the diagnosis and treatment of prostate conditions, including prostate cancer. He practises privately at HCA Healthcare UK and is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust.
Prof. Emberton qualified in medicine from the University of London and completed specialist training in urology, achieving Fellowship of the Royal College of Surgeons. He was awarded a Doctor of Medicine degree following research at the Royal College of Surgeons and has held senior academic and leadership roles at University College London, including Dean of the Faculty of Medical Sciences.
His clinical expertise focuses on prostate disease, including prostate cancer, benign prostatic hyperplasia and prostatitis. He is internationally recognised for pioneering work in advanced imaging techniques and minimally invasive treatments, including focal therapy, high-intensity focused ultrasound and image-guided interventions to improve diagnosis and reduce treatment-related side effects.
Prof. Emberton leads an internationally recognised research programme focused on improving the accuracy of prostate cancer diagnosis and developing less invasive treatment options. His work has contributed to changes in clinical practice, including the adoption of MRI in prostate cancer diagnosis and the development of targeted therapies.
He has published extensively in leading medical journals and is widely regarded as a key figure in advancing prostate cancer care. He is committed to delivering evidence-based, patient-centred care with a focus on improving outcomes and quality of life for men with urological conditions.
Areas of expertise
- Active surveillance
- Cyrosurgery
- Focal therapy
- Focal therapy
- High intesntivy focused ultrasound
- Minimally-invasive treatment for prostate cancer, which aims to preserve prostate function
- MRI scan
- Non-invasive diagnosis
- Non-invasive diagnosis incorporating MRI and targeted biopsies where necessary
- Photo therapy
- Photo-dynamic therapy
- Prostate cancer
- Salvage therapy
- Use of biomarkers to refine the risk stratification of men who been recently diagnosed with prostate cancer
- Vascular targeted therapy
Frequently asked questions
What are the common symptoms that your patients tend to present with?
Patients visit me with prostate problems. Sometimes there are symptoms such as when a man has lower urinary tract symptoms, and at other times, a higher frequency and urgency of urination at night.
A much more common symptom is patients presenting with a prostate cancer risk or a prostate cancer diagnosis, which is my most frequent consultation. That would be a man with an elevated PSA or a positive family history who wants reassurance in that regard.
In terms of the treatments that I'm recognised for, we have pioneered the use of MRI in prostate cancer, which is now globally accepted. We have pioneered the use of minimally-invasive therapies, which are increasingly being used around the world. Patients come from all over the world to me to get advice in both these areas.
What are the treatments that you're able to offer your patients?
Possibly, better than any other centre in the world, we are able to offer patients the treatment that is most suited to themselves, their prostates and their prostate cancer. What we do, unlike any other centre in the world, is use a number of energy sources to selectively treat the cancer and preserve the prostate and, therefore, maximise the cure rate whilst also maximising the chances of them having no symptoms or side effects as a result of their treatment.
We focus on improving the therapeutic ratio for men with early prostate cancer and avoiding, where possible, the use of surgery or radiotherapy.
What are your areas of sub-specialist interest?
I'm a clinician scientist. Half my week is spent doing clinical science and half is spent doing medicine. The two dovetail each other and, therefore, the trials that I do in diagnosis and therapy, we implement in the patients that we treat.
My laboratory, if we can use the word, is the clinic. It's from there that we recruit patients into Phase I, Phase II and Phase III clinical studies.
In addition to the above, I also focus on younger patients, young adults or adolescents who present with primary problems that need assessment.
Professional memberships
























